Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Can complexity be commercialized?

Big pharma is dabbling in systems biology, a few brave entrepreneurs are trying to make a business out of it, but investor caution may keep those in the field from really making it big in drug development.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Top-down versus bottom-up approaches.
Figure 2: Cell cycle model showing G1-S transition and the highly connected p53 node.
Figure 3: Beyond Genomics Correlation Network: Up- and downregulated genes, proteins and metabolites in a mammalian disease model versus controls ('normals').

References

  1. Skomorovski, K. et al. New TPO treatment schedules of increased safety and efficacy: pre-clinical validation of a thrombopoiesis simulation model. British J. Haematol. 123, 683–691 (2003).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mack, G. Can complexity be commercialized?. Nat Biotechnol 22, 1223–1229 (2004). https://doi.org/10.1038/nbt1004-1223

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1004-1223

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing